DICE Therapeutics (NASDAQ:DICE) Shares Gap Down to $22.65

Shares of DICE Therapeutics, Inc. (NASDAQ:DICEGet Rating) gapped down before the market opened on Monday . The stock had previously closed at $22.65, but opened at $21.38. DICE Therapeutics shares last traded at $18.26, with a volume of 12,154 shares changing hands.

Analysts Set New Price Targets

A number of brokerages have recently commented on DICE. Stifel Nicolaus started coverage on shares of DICE Therapeutics in a report on Tuesday, September 6th. They set a “buy” rating and a $37.00 target price on the stock. HC Wainwright started coverage on shares of DICE Therapeutics in a research note on Monday, July 18th. They issued a “buy” rating and a $40.00 price target on the stock. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $44.80.

DICE Therapeutics Trading Down 2.2 %

The company has a market cap of $706.90 million and a P/E ratio of -4.84. The stock’s 50 day moving average is $18.07 and its 200-day moving average is $17.66.

Hedge Funds Weigh In On DICE Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Northpond Ventures LLC bought a new position in DICE Therapeutics during the 4th quarter valued at about $83,343,000. Price T Rowe Associates Inc. MD lifted its stake in DICE Therapeutics by 12.6% during the 2nd quarter. Price T Rowe Associates Inc. MD now owns 2,414,624 shares of the company’s stock valued at $37,475,000 after acquiring an additional 270,940 shares during the period. Driehaus Capital Management LLC lifted its stake in DICE Therapeutics by 5.0% during the 2nd quarter. Driehaus Capital Management LLC now owns 2,230,538 shares of the company’s stock valued at $34,618,000 after acquiring an additional 105,310 shares during the period. FMR LLC lifted its stake in DICE Therapeutics by 460.0% during the 2nd quarter. FMR LLC now owns 1,910,328 shares of the company’s stock valued at $29,648,000 after acquiring an additional 1,569,206 shares during the period. Finally, Deep Track Capital LP bought a new position in DICE Therapeutics during the 4th quarter valued at about $33,941,000. Institutional investors own 95.42% of the company’s stock.

About DICE Therapeutics

(Get Rating)

DICE Therapeutics, Inc, a biopharmaceutical company, builds various oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. Its platform DELSCAPE, is designed to discover selective oral small molecules to modulate protein-protein interactions (PPIs) as effectively as systemic biologics.

Featured Stories

Receive News & Ratings for DICE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DICE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.